Chimerix (CMRX)
(Delayed Data from NSDQ)
$0.97 USD
-0.04 (-3.91%)
Updated May 10, 2024 04:00 PM ET
After-Market: $0.96 -0.01 (-1.08%) 7:58 PM ET
4-Sell of 5 4
C Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CMRX 0.97 -0.04(-3.91%)
Will CMRX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CMRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CMRX
Chimerix (CMRX) Reports Q2 Loss, Misses Revenue Estimates
Cerus (CERS) Reports Q2 Loss, Lags Revenue Estimates
CMRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Chimerix (CMRX) Reports Q1 Loss, Misses Revenue Estimates
Chimerix (CMRX) Loses -24.68% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Green Thumb Industries Inc. (GTBIF) Q4 Earnings Lag Estimates
Other News for CMRX
Buy Rating Justified by Chimerix’s Upcoming Catalysts and Strong Financials
Strong Buy Rating for Chimerix on Robust Financials and Promising Drug Pipeline
Chimerix Inc (CMRX) Q1 2024 Earnings Call Transcript Highlights: Strategic Developments and ...
CMRX Stock Earnings: Chimerix Misses EPS for Q1 2024
Chimerix, Inc. (CMRX) Q1 2024 Earnings Call Transcript